Increased risk of end-stage renal disease in patients with systemic sclerosis

References

• Poudel DR, Derk CT. Mortality and survival in systemic sclerosis: a review of recent literature. Curr Opin Rheumatol 2018;30:588–93.
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Yu KH, Chou IJ, Tseng WY, Chang HC, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011;40:373–8.
   PubMed Web of Science ®Google Scholar
• Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol 2012;24:669–76.
   PubMed Web of Science ®Google Scholar
• Kingdon EJ, Knight CJ, Dustan K, Irwin AG, Thomas M, Powis SH, et al. Calculated glomerular filtration rate is a useful screening tool to identify scleroderma patients with renal impairment. Rheumatology (Oxford) 2003;42:26–33.
   PubMed Web of Science ®Google Scholar
• Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005;32:649–55.
   PubMed Web of Science ®Google Scholar
• Scheja A, Bartosik I, Wuttge DM, Hesselstrand R. Renal function is mostly preserved in patients with systemic sclerosis. Scand J Rheumatol 2009;38:295–8.
   PubMed Web of Science ®Google Scholar
• Turk M, Pope JE. The frequency of scleroderma renal crisis over time: a meta analysis. J Rheumatol 2016;43:1350–5.
   PubMed Web of Science ®Google Scholar
• Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M, et al. Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant 2012;27:4398–403.
   PubMed Web of Science ®Google Scholar
• Abbott KC, Trespalacios FC, Welch PG, Agodoa LY. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002;15:236–40.
   PubMed Web of Science ®Google Scholar
• Hruskova Z, Pippias M, Stel VS, Abad-Diez JM, Benitez Sanchez M, Caskey FJ, et al. Characteristics and outcomes of patients with systemic sclerosis (Scleroderma) requiring renal replacement therapy in Europe: results from the ERA-EDTA registry. Am J Kidney Dis 2019;73:184–93.
   PubMed Web of Science ®Google Scholar
• Dehejia RH, Wahba Sjroe, Statistics. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151–61.
   Web of Science ®Google Scholar
• Cheng TM. Reflections on the 20th anniversary of Taiwan’s single-payer National Health Insurance System. Health Aff (Millwood) 2015;34:502–10.
   PubMed Web of Science ®Google Scholar
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
   PubMed Web of Science ®Google Scholar
• Lai CC, Wang SH, Chen WS, Liu CJ, Chen TJ, Lee PC, et al. Increased risk of osteoporotic fractures in patients with systemic sclerosis: a nationwide population-based study. Ann Rheum Dis 2015;74:1347–52.
   PubMed Web of Science ®Google Scholar
• Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 2010;172:1092–7.
   PubMed Web of Science ®Google Scholar
• Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387–98.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. ‘United States renal data system 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012;59:e1–420.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr., Osial TA Jr., Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779–86.
   PubMed Web of Science ®Google Scholar
• Sexton DJ, Reule S, Foley RN. End-stage kidney disease from scleroderma in the United States, 1996 to 2012. Kidney Int Rep 2018;3:148–54.
   PubMed Web of Science ®Google Scholar
• Bertrand D, Dehay J, Ott J, Sberro R, Brunelle C, Kamar N, et al. Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transpl Int 2017;30:256–65.
   PubMed Web of Science ®Google Scholar
• Caron M, Hudson M, Baron M, Nessim S, Steele R. Longitudinal study of renal function in systemic sclerosis. J Rheumatol 2012;39:1829–34.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600–3.
   PubMed Web of Science ®Google Scholar
• Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr., Steen VD, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983;62:335–52.
   PubMed Web of Science ®Google Scholar
• Bose N, Chiesa-Vottero A, Chatterjee S. Scleroderma renal crisis. Semin Arthritis Rheum 2015;44:687–94.
   PubMed Web of Science ®Google Scholar
• Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352–7.
   PubMed Web of Science ®Google Scholar
• Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485–94.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014;86:896–904.
   PubMed Web of Science ®Google Scholar
• Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013;106:839–48.
   PubMed Web of Science ®Google Scholar
• Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev 2018;17:882–9.
   PubMed Web of Science ®Google Scholar
• Gaultier JB, Hot A, Cathebras P, Grange C, Ninet J, Rousset H. [Systemic sclerosis in men]. Rev Med Interne 2008;29:181–6.
   PubMed Web of Science ®Google Scholar
• Peoples C, Medsger TA Jr., Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord 2016;1:177–240.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940–4.
   PubMed Web of Science ®Google Scholar
• Steen VD. Kidney involvement in systemic sclerosis. Presse Med 2014;43:e305–14.
   PubMed Web of Science ®Google Scholar
• Alba MA, Velasco C, Simeon CP, Fonollosa V, Trapiella L, Egurbide MV, et al. Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients. Medicine (Baltimore) 2014;93:73–81.
   PubMed Web of Science ®Google Scholar
• Choi HS, Han KD, Jung JH, Kim CS, Bae EH, Ma SK, et al. The risk of end-stage renal disease in systemic lupus erythematosus: a nationwide population-based study in Korea. Medicine (Baltimore) 2019;98:e16420.
   PubMed Web of Science ®Google Scholar
• Siva B, McDonald SP, Hawley CM, Rosman JB, Brown FG, Wiggins KJ, et al. End-stage kidney disease due to scleroderma–outcomes in 127 consecutive ANZDATA registry cases. Nephrol Dial Transplant 2011;26:3165–71.
   PubMed Web of Science ®Google Scholar
• Valenzuela A, Yaqub A, Fiorentino D, Krishnan E, Chung L. Validation of the ICD-9-CM code for systemic sclerosis using updated ACR/EULAR classification criteria. Scand J Rheumatol 2015;44:253–5.
   PubMed Web of Science ®Google Scholar